Breast IHC markers explained

GATA3, Mammaglobin — and What Breast Markers Mean

When a report lists GATA3 or mammaglobin with a plus or minus sign, the pathologist is recording where the cancer is thought to have started — not how serious it is. These markers exist to answer one question: did this cancer originate in breast tissue?

Medically reviewed by Dr. Mohammed Imaduddin, Surgical Oncologist, MBBS · MS (General Surgery) · M.Ch (Surgical Oncology) · Last reviewed September 2026

Origin markers, not grade markers — GATA3 and mammaglobin record where a cancer came from, not how aggressive it is.
Used most in metastatic workup — They are ordered when cancer is found at a site away from the breast, to confirm whether the breast was the primary source.
Read as a panel, not alone — No single marker is definitive. The pathologist looks at several together to reach a conclusion.
Positive means present, not advanced — A positive result means the protein was found in the cells — it is a clue to origin, not a severity score.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

GATA3 positive means the laboratory found a protein strongly associated with breast tissue in the cancer cells being examined. It is used alongside other markers to confirm that a cancer — often found at a distant site — originated in the breast. It is not a measure of how advanced the cancer is.

When does a pathologist look for breast markers?

When cancer is found in a lymph node, the liver, a bone, or another site away from the breast, the pathologist needs to know where it started. The primary site is what defines which cancer it is.

Breast markers are proteins that breast cells produce in far larger amounts than most other tissues. Finding them in a tumour biopsy is evidence that those cells originally came from breast tissue.

No single marker is definitive on its own. The pathologist reads a set of markers together — called a panel — because the pattern across several results is more reliable than any one result alone.

What does each marker on your report mean?

GATA3: A protein found in breast cell nuclei. One of the most sensitive markers for breast origin — positive in a large proportion of breast cancers. Also positive in some bladder and urothelial cancers, which is why it is always read as part of a panel rather than alone.
Mammaglobin: A protein made almost exclusively by breast tissue. More specific than GATA3 — rarely positive in non-breast cancers — but positive in a smaller proportion of breast cancers overall. Most useful as a confirmatory marker when GATA3 is also positive.
GCDFP-15: Short for gross cystic disease fluid protein-15. Highly specific for breast origin but less sensitive than GATA3. Can also be positive in apocrine sweat gland tumours. Your report may use the abbreviation or write it in full.
ER (oestrogen receptor): Records whether the cancer cells carry receptors for oestrogen. Reported as positive or negative, sometimes with a percentage score. Your oncologist interprets what this means for your care — it is not a marker of origin in the way GATA3 is.
PR (progesterone receptor): Records whether cancer cells carry receptors for progesterone. Reported the same way as ER. Your oncologist reads ER and PR together. The significance of these results for your treatment is a conversation for your team.
HER2: Records whether cells produce unusually high levels of the HER2 protein. Scored 0, 1+, 2+, or 3+. A 2+ result usually requires a second test called ISH to confirm whether the level is truly elevated. Your oncologist interprets this result.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

Did you know?

Breast IHC markers can identify breast origin even in patients who had no previous breast cancer diagnosis — including when cancer is found in the liver, lungs, or bones with no known primary tumour.

This is why GATA3 and mammaglobin are a standard part of the panel when the starting point of a cancer is unknown.

Source: ESMO Clinical Practice Guidelines: Cancers of Unknown Primary Site

Can one positive marker alone confirm a cancer's origin?

Does GATA3 positive alone confirm breast origin?

No. GATA3 positive is strong evidence for breast tissue, but the pathologist reaches their conclusion from the full panel. Because GATA3 can also be positive in bladder and urothelial cancers, a single positive result is not conclusive. The combination — GATA3 alongside mammaglobin, GCDFP-15, and clinical findings — is what allows a confident conclusion about origin.

Can GATA3 be positive in a cancer that did not start in the breast?

Yes. GATA3 can be positive in some bladder and urothelial cancers, and occasionally in other tumour types. This is precisely why pathologists do not rely on a single marker. When there is ambiguity, they add markers specific to other possible primary sites — lung, kidney, and gastrointestinal cancers each have their own characteristic patterns — to distinguish between them.

What does a negative result for any of these markers mean?

A negative result means the protein was not detected at a meaningful level. It does not by itself rule out breast origin, because not all breast cancers produce every marker in detectable amounts. Some breast cancers are less likely to be strongly positive for GATA3 or mammaglobin. A negative result on one marker is always interpreted in context with the rest of the panel.

Why are so many different markers listed on the same report?

Because no single protein is unique to breast tissue in every cancer. By testing several markers together, the pathologist looks for a pattern rather than a single positive answer. Each result adds to or subtracts from the probability of a particular origin. The combination also helps exclude other primary sites so the conclusion can be narrowed down reliably.

What do the plus and minus signs next to each marker mean?

A plus sign means the protein was detected. A minus sign means it was not detected at a meaningful level. Some reports use 1+, 2+, or 3+ to show how strongly a protein is present — strong positivity means a larger proportion of cells are producing it at a high level. Your report's key or legend will explain the scoring system your laboratory uses.

Should I ask my oncologist anything specific about these results?

It is reasonable to ask three things: which markers were positive, which were negative, and what the panel as a whole suggests about where the cancer originated. You do not need to understand every marker in detail — your oncologist will explain the ones most relevant to your situation. If the answer is not clear after the first conversation, it is entirely reasonable to ask again.

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

IHC Markers Explained

Breast Markers: ER, PR, HER2, Ki-67

False Negatives & Accuracy

Inadequate, Inconclusive & Repeat Biopsy

Labs, Slides, Blocks & Second Opinions

Molecular & Genomic Testing

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

What does GATA3 positive mean in simple terms?

GATA3 positive means the laboratory detected a protein in the cancer cells that is strongly linked to breast tissue. It is evidence that the cancer originated in the breast, particularly when the cancer has been found at a distant site. A positive GATA3 result on its own does not confirm the diagnosis — your oncologist reads it alongside the full panel and your clinical picture.

Can GATA3 be positive in men?

Yes. Male breast cancer exists, and GATA3 can be positive when it does. The marker functions the same way regardless of the patient's sex — it records whether the protein associated with breast-type cells is present in the tumour. If GATA3 appears on a report for a male patient, the oncologist interprets it in exactly the same clinical context.

Is a negative GATA3 result reassuring?

Not necessarily. Some breast cancers are less likely to express GATA3 strongly, and a negative result on one marker does not by itself rule out breast origin. Pathologists read the full panel, and the combination of results gives a more reliable answer than any one marker alone. Your oncologist will explain what a negative result means in the context of your specific report.

What is the difference between GATA3 and mammaglobin?

Both point to breast origin, but they work differently. GATA3 is more sensitive — positive in a larger proportion of breast cancers — but can also be positive in some non-breast cancers. Mammaglobin is more specific — rarely positive in non-breast tumours — but positive in a smaller proportion of breast cancers. Together they give a more reliable answer than either alone.

Who interprets what these markers mean for my treatment?

Your treating oncologist. The pathologist reports what the laboratory found. The oncologist reads that report alongside your imaging, your biopsy findings, and your medical history to decide what it means for your care. The treatment implications of markers like ER, PR, and HER2 in particular are a conversation to have directly with your oncologist, not something this page can interpret for you.

Will I need more tests after these markers come back?

Possibly. If the panel points clearly to breast origin, your oncologist may move to the next stage of planning your care. If results are ambiguous — one marker positive, others negative — additional markers may be ordered, or the sample may be reviewed by a specialist pathologist. Sometimes imaging is added to look for a primary tumour that has not yet been detected. Your oncologist will tell you what comes next.

Full index